Business Wire

CHINA-YIWU-IMPORTED-FAIR

13.11.2020 14:40:11 CET | Business Wire | Press release

Share
2020 Yiwu Imported Commodities Fair is Being Held in World Capital of Small Commodities

The 2020 China Yiwu Imported Commodities Fair opened in Yiwu City on November 13, 2020 and will continue until the 16th . As a professional, international and market-oriented event, Yiwu Imported Commodities Fair is committed to becoming China's top brand for imported consumer goods.

View the 2020 Yiwu Imported Commodities Fair album:

https://as.alltuu.com/v4/albumset/1001142273/

The Fair has five pavilions, namely Quality Life (Wine & Coffee), Asia Pavilion, Europe Pavilion, America-Oceania-Africa Pavilion, and Quality Life (Home Decoration Materials), to exhibit products from 78 countries and regions.

The Fair attracted nearly 1,000 exhibitors, one third of which were newcomers. Among them were the second largest butter cookie manufacturer from Denmark, the well-known organic superfood manufacturer from Germany, and many well-known Australian companies. Meanwhile, as this year’s Fair was opened right after the closure of China International Import Expo (CIIE) in Shanghai, 93 CIIE exhibitors also came to the Fair, a significant increase from last year’s 26.

Government participants included the Consulate General of the Republic of Korea in Shanghai, the Consulate General of the Socialist Republic of Vietnam in Shanghai, the Consulate General of the Eastern Republic of Uruguay in Shanghai, the China-Britain Business Council, The Canada International Trade Promotion Society, and the West Australia Trade and Investment Promotion Council.

As the country of honor, Russia brought more than 30 companies including the Russian Agricultural Group. Representatives from the Russian Consulate in Shanghai, the Russian Cultural Center in Beijing, and the Russian Export Center Group attended the Fair to showcase various aspects of the country, including economy, trade, culture and arts.

Varied supporting activities were prepared for exhibitors, buyers and visitors. In addition to a number of business themed forums and business matchmaking meetings, multiple cultural activities were held. For instance, Russia brought ethnic performances and food appreciation; the British Pavilion invited visitors on site to experience the purest British fashion; the Latte Art competition in the coffee products area attracted a lot of attention.

Another highlight of the Fair was the debut of the mascot “Jin Jin”, a lively and lovely white gosling, whose vibrant cartoon image reflects the enthusiasm and diversity of the Fair, greatly enhancing the image awareness of the Fair.

For more:

Official website: http://www.importfair.cn/en

Facebook: https://www.facebook.com/yiwuimportfair/

Instagram: https://www.instagram.com/yiwu_importedfair/

Link:

ClickThru

Social Media:

https://www.facebook.com/yiwuimportfair/

https://www.facebook.com/officialyiwufair/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye